Skip to main content

West Pharmaceutical Services Value Stock - Dividend - Research Selection

West pharmaceutical services

ISIN: US9553061055 , WKN: 864330

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

2026-08-07
DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

AMN Q2 Earnings Beat Estimates on Staffing and Search Growth, Stock Up

2026-08-07
AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.

DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up

2026-08-07
Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

2026-08-06
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised

2026-08-06
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised

2026-08-06
McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.

Broad-Based Growth Lifted West Pharmaceuticals (WST) in Q2

2026-08-06
Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI […]

Can Segment Strength Offset Headwinds for BD Stock Before Q3 Earnings?

2026-08-05
BDX's Medical Essentials and Interventional strength may drive third-quarter fiscal 2026 results, but China, vaccines and projected declines weigh on expectations.

HNGE Q2 Earnings Meet Estimates, Sales Top, '26 View Raised, Stock Up

2026-08-05
Hinge Health's Q2 revenues jump 53% as stronger member yield, margin gains and raised 2026 guidance reinforce business momentum.

COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised

2026-08-05
Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.